Ying Liu1, Ying Liao1, Linlin Xiang1, Kuo Jiang2, Siyao Li2, Mingmei Huangfu2, Shilong Sun3. 1. Department of Toxicology, School of Public Health, Jilin University, Changchun, 130021, China. 2. Ministry of Health Key Laboratory of Radiobiology, Jilin University, Changchun, 130021, China. 3. Ministry of Health Key Laboratory of Radiobiology, Jilin University, Changchun, 130021, China. slsun@jlu.edu.cn.
Abstract
BACKGROUND: Specific circulating autoantibodies are produced by host immune systems to respond to antigens that arise during tumorigenesis. To achieve auxiliary diagnosis, the present study was designed to test whether circulating autoantibodies against tumor-associated antigens (TAAs) were altered in early breast cancer. METHODS: A total of 102 breast cancer patients and 146 age-matched healthy volunteers were recruited to participate in this study. Autoantibody expression was tested using in-house developed enzyme-linked immunosorbent assay (ELISA) with linear peptide envelope antigens derived from TAAs. RESULTS: Student's t tests showed that expression of autoantibodies against the panel (p16, c-myc, TP53, and ANXA-1) was significantly higher in the breast cancer group, stage I and II breast cancer group, and stage III and IV breast cancer group than in the healthy control group (p < 0.001, p < 0.001, p < 0.001). The sensitivities of detection of the panel (90% specificity) in these groups were 33.3%, 31.7%, and 33.3%, respectively, significantly higher than that of any single autoantibody. CONCLUSION: The panel of autoantibodies is more sensitive than single TAA autoantibody detection and may be used as biomarkers for early diagnosis of breast cancer.
BACKGROUND: Specific circulating autoantibodies are produced by host immune systems to respond to antigens that arise during tumorigenesis. To achieve auxiliary diagnosis, the present study was designed to test whether circulating autoantibodies against tumor-associated antigens (TAAs) were altered in early breast cancer. METHODS: A total of 102 breast cancerpatients and 146 age-matched healthy volunteers were recruited to participate in this study. Autoantibody expression was tested using in-house developed enzyme-linked immunosorbent assay (ELISA) with linear peptide envelope antigens derived from TAAs. RESULTS: Student's t tests showed that expression of autoantibodies against the panel (p16, c-myc, TP53, and ANXA-1) was significantly higher in the breast cancer group, stage I and II breast cancer group, and stage III and IV breast cancer group than in the healthy control group (p < 0.001, p < 0.001, p < 0.001). The sensitivities of detection of the panel (90% specificity) in these groups were 33.3%, 31.7%, and 33.3%, respectively, significantly higher than that of any single autoantibody. CONCLUSION: The panel of autoantibodies is more sensitive than single TAA autoantibody detection and may be used as biomarkers for early diagnosis of breast cancer.
Entities:
Keywords:
Autoantibody; Biomarker; Breast cancer; Early prognostic
Authors: A Keshaviah; S Dellapasqua; N Rotmensz; J Lindtner; D Crivellari; J Collins; M Colleoni; B Thürlimann; C Mendiola; S Aebi; K N Price; O Pagani; E Simoncini; M Castiglione Gertsch; R D Gelber; A S Coates; A Goldhirsch Journal: Ann Oncol Date: 2007-01-20 Impact factor: 32.976
Authors: Asmaa M El-Rasikh; Haithem A M Farghali; Hisham A Abdelrahman; Mostafa Elgaffary; Shaymaa Abdelmalek; Ibrahim A Emam; Magdy A Ghoneim; Salah A Selim Journal: Sci Rep Date: 2021-05-17 Impact factor: 4.379
Authors: Makoto Kobayashi; Hiroyuki Katayama; Ehsan Irajizad; Jody V Vykoukal; Johannes F Fahrmann; Deepali L Kundnani; Chuan-Yih Yu; Yining Cai; Fu Chung Hsiao; Wei-Lei Yang; Zhen Lu; Joseph Celestino; James P Long; Kim-Ann Do; Karen H Lu; Jon J Ladd; Nicole Urban; Robert C Bast; Samir M Hanash Journal: Cancers (Basel) Date: 2020-02-19 Impact factor: 6.639